Daniel C. Cho

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial”.

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine(2023)10.1038/s41591-023-02321-8

N/A

4.1DataRank · unranked

307 citations

Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein +18 more

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005147

N/A

1.7DataRank · unranked

66 citations

Michael J. Pishvaian, Margaret K. Callahan, Amy Weise, Branimir I. Šikić, Osama E. Rahma +19 more

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002446

N/A

1.0DataRank · unranked

26 citations

Omid Hamid, Elisabeth G.E. de Vries, Patrick A. Ott, Javier García-Corbacho, Valentina Boni +8 more